Novartis’ Pluvicto Shows Promise in Early Stage Prostate Cancer

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium...

Keep Reading →